Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of New York Mellon Corp (BNY) vs Invesco Ltd. (IVZ) Price & Performance

Bank of New York Mellon CorpTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Bank of New York Mellon Corp vs Invesco Ltd. — how do they compare? Bank of New York Mellon Corp trades at $159.06 (market cap $106.05B), while Invesco Ltd. trades at $30.03 (market cap $12.74B). The key difference: Bank of New York Mellon Corp is far larger — about 8.3× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.99%). Which is the better fit depends on your goals.

BNYIVZ
Market Cap
$106.05B$12.74B
Sector
FinancialsFinancials
52-Week High
$154.50$29.44
52-Week Low
$95.16$16.74
Dividend Yield
1.37%2.99%
Enterprise Value
$22.98B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of New York Mellon Corp

BNY trades at $151.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue growth has been steady, rising from $16.0B in 2022 to $19.8B in 2025, while net income margin improved to 29.21%. Analyst consensus is mixed with 38% buy ratings but a $156 price target suggesting modest upside. Recent news highlights strong fee income expectations and a planned 19% dividend increase.

BNY demonstrates solid fundamental strength with improving profitability and consistent earnings beats. The stock offers potential upside to analyst targets and dividend growth, but faces risks from high investing cash outflows and competitive pressures. Current valuation metrics appear reasonable relative to historical performance, though investors should monitor Q2 earnings results for confirmation of growth trajectory.

Invesco Ltd.

Invesco (IVZ) trades at $28.4, down 2.0% on the day, with a bullish technical signal driven by moving averages. The company reported mixed earnings, beating in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $6.38B in 2025. Analyst consensus is a Buy with a $30.50 price target, and recent news highlights upgrades and strong momentum.

The outlook is cautiously optimistic given analyst support and improving cash flow, but risks include negative net income margins and competitive pressures in asset management. Upside hinges on earnings recovery and AUM growth, while macroeconomic volatility remains a headwind.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bank of New York Mellon Corp

BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.

Read more on BNY

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ